BioNTech's Next Act: Shareholders Back Oncology Pivot as ASCO Data and June 30 Update Loom Over Stagnant Stock

BioNTech's stock hovers near 52-week lows as the company pivots to oncology, with pivotal ASCO data and board succession plans due in May and June 2026.

BioNTech's stock sits at €76.95, roughly a quarter below its 52-week peak of €101.90 and barely 6% above the year's trough of €72.50. The market is clearly demanding proof of concept for the company's audacious transition from pandemic champion to cancer specialist — and the next few weeks will deliver two critical tests.

Shareholder Mandate for the New Board

At the virtual annual general meeting on 15 May, investors representing 92% of the voting capital gave unanimous approval to every resolution on the agenda. The most consequential move was the expansion of the supervisory board from six to eight seats. Helmut Jeggle remains chairman, while Prof. Iris Löw-Friedrich and Susanne Schaffert join — both bring deep clinical development and oncology credentials.

The timing is deliberate. Co-founders Ugur Sahin and Özlem Türeci are stepping back by the end of 2026 to establish a new independent venture, and the enlarged board will oversee the succession search already underway. The restructuring at BioNTech's Gaithersburg, Maryland site, including job cuts and capacity adjustments, is another sign of the operational overhaul now in progress.

ASCO Provides the First Clinical Verdict

From 29 May, the oncology pipeline will face its most public scrutiny yet at the American Society of Clinical Oncology annual meeting. Phase 2 data from the ROSETTA-Lung-02 study are expected for pumitamig, the lead programme developed with Bristol Myers Squibb. Five new pivotal trials for the candidate are already recruiting — in triple-negative breast cancer, colorectal carcinoma and two non-small-cell lung cancer indications — with early Phase 3 interim readouts anticipated in 2026.

Another programme is edging closer to regulatory submission. Trastuzumab pamirtecan, an antibody-drug conjugate targeting HER2-positive endometrial cancer, has secured both Fast Track and Breakthrough Therapy designations from the FDA. A Phase 2 study delivered a confirmed objective response rate of 47.9% in centrally tested patients, and BioNTech plans to file a Biologics License Application in the US this year, pending regulatory feedback.

Financial Discipline Amid Heavy Spending

The transition is expensive. For the first quarter of 2026, BioNTech posted revenue of €118.1 million and a net loss of €531.9 million. That follows a full-year 2024 result of roughly €2.75 billion in revenue and a net loss of €665 million, driven by massive investment in the mRNA cancer pipeline. Still, the company holds around €16.8 billion in cash reserves enough to fund ongoing development. Management guided for full-year 2025 revenue of $2.3 billion to $2.6 billion and recently authorised a share buyback of up to $1 billion over twelve months.

The Next Catalyst on the Calendar

While ASCO dominates headlines at the end of May, BioNTech has a second near-term marker on 30 June, when it publishes what it has labelled a quarterly communication. That update will likely provide early colour on pipeline progress and cost measures. The following formal earnings presentation is scheduled for 4 August.

Analysts, for now, remain broadly bullish. The consensus price target sits at $118.44, implying substantial upside from current levels — but that gap will narrow only if the clinical data and June 30 update can convince a sceptical market that the pivot to oncology has genuine momentum.